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Introduction
Atrial fibrillation (AF) is an important and highly prevalent arrhythmia, which is associated 
with significantly increased morbidity and mortality, including a four- to five-fold increased 
risk for stroke,1,2 a two-fold increased risk for dementia,3,4 a three-fold risk for heart 
failure,2 a two-fold increased risk for myocardial infarction,5,6 and a 40–90% increased risk 
for overall mortality.2,7 The constantly increasing number of AF patients and recognition of 
increased morbidity, mortality, impaired quality of life, safety issues, and side effects of 
rhythm control strategies with antiarrhythmic drugs, and high healthcare costs associated 
with AF have spurred numerous investigations to develop more effective treatments for AF 
and its complications.8 Although AF treatment has been studied extensively, AF prevention 
has received relatively little attention, while it has paramount importance in the prevention 
of morbidity and mortality, and complications associated with arrhythmia and its treatment. 
Current evidence shows a clear association between the presence of modifiable risk factors 
and the risk of developing AF.
By implementing AF risk reduction strategies aiming at risk factors such as obesity, 
hypertension, diabetes, and obstructive sleep ap-noea (OSA), which are interrelated, we 
impact upon the escalating incidence of AF in the population and ultimately decrease the 
healthcare burden of associated co-morbidities of AF.
To address this issue, a Task Force was convened by the European Heart Rhythm 
Association and the European Association of Cardiovascular Prevention and Rehabilitation, 
endorsed by the Heart Rhythm Society and Asia-Pacific Heart Rhythm Society, with the 
remit to comprehensively review the published evidence available, to publish a joint 
consensus document on the prevention of AF, and to provide up-to-date consensus 
recommendations for use in clinical practice. In this document, our aim is to summarize the 
current evidence on the association of each modifiable risk factor with AF and the available 
data on the impact of possible interventions directed at these factors in preventing or 
reducing the burden of AF. While the evidence on AF prevention is still emerging, the topic 
is not fully covered in current guidelines and some aspects are still controversial. Therefore, 
there is a need to provide expert recommendations for professionals participating in the care 
of at-risk patients and populations, with respect to addressing risk factors and lifestyle 
modifications.
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Health economic considerations
Atrial fibrillation is a costly disease, both in terms of direct, and indirect costs, the former 
being reported by cost of illness studies as per-patient annual costs in the range of US 
$2000–14200 in North America and of €450–3000 in Europe.9
In individuals with AF or at risk of developing AF, any effective preventive measure, 
intervention on modifiable risk factors or comorbidities, as well as any effective 
pharmacological or non-pharmacological treatment has the aim to reduce AF occurrence, 
thromboembolic events and stroke, morbidity and, possibly, mortality related to this 
arrhythmia. Apart from the clinical endpoints, achievement of these goals has economic 
significance, in terms of positive impact on direct and indirect costs and favourable cost–
effectiveness at mid- or long-term, in the perspective of healthcare systems.10–12
In view of the epidemiological profile of AF and progressive aging of the population,13 an 
impressive increase of patients at risk of AF or affected by AF,14 also in an asymptomatic 
stage, is expected in the next decades, inducing a growing financial burden on healthcare 
systems, not only in Europe and North America, but also worldwide.15,16
In consideration of this emerging epidemiological threat due to AF, it is worth considering a 
paradigm shift, going beyond the conventional approach of primary prevention based on 
treatment of AF risk factors, but, instead, considering the potential for ‘primordial’ 
prevention, defined as prevention of the development of risk factors predisposing to AF in 
the first place.17 This approach, aimed at avoiding the emergence and penetration of risk 
factors into the population, has been proposed in general terms for the prevention of 
cardiovascular diseases17 and should imply combined efforts of policymakers, regulatory 
and social service agencies, providers, physicians, community leaders, and consumers, in an 
attempt to improve social and environmental conditions, as well as individual behaviours, in 
the pursuit of adopting healthy lifestyle choices.16 Since a substantial proportion of incident 
AF events can be attributable to elevated or borderline levels of risk factors for AF,18 this 
approach could be an effective way to reduce the financial burden linked to AF 
epidemiology. In terms of individual behaviour and adoption of a ‘healthy lifestyle’, it is 
worth considering that availability of full healthcare coverage (through health insurance or 
the healthcare system) may in some cases facilitate the unwanted risk of reducing, at an 
individual level, the motivation to adopt all the preventive measures that are advisable, in 
line with the complex concept of ‘moral hazard effect’.19 Patient education and patient 
empowerment are the correct strategies for avoiding this undesirable effect.
Obesity
Obesity is associated with the development of AF and has an important impact on AF-
related clinical outcomes (Table 1).20–25 A strategy of weight control may reduce the 
increasing incidence of AF making it an important subject in the prevention of AF22,26,27 
and long-term benefit for patients at risk for developing AF.28 The strongest evidence for 
adverse clinical outcomes comes from various large cohort studies (Table 1). The 
Framingham Heart Study23 revealed that obesity is an important predictor of development of 
AF in adults and demonstrated via echocardiographic data, that the relationship between 
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body size and AF is mediated by left atrial enlargement and inflammation.29 A recent 
community-based study in the Netherlands confirmed that, in addition to the conventional 
risk factors for AF, body mass index (BMI) was strongly associated with AF with a 45% 
increased risk of AF with every five points of BMI increase.25 This study supports the notion 
that BMI should be regarded as a validated risk factor for incident AF.25 Indeed, obesity was 
the strongest contributor to incident AF in a number of studies, worldwide.20,21,25,30 In the 
Guangzhou Biobank Cohort Study, for example, both general and central obesity were 
associated with increased risk of AF in an Asian population with generally much lower 
levels of obesity compared with Western countries.21
A large Danish prospective population-based cohort study,24 among 55 273 men and women 
aged 50–64 years of age at recruitment, also confirmed the association between obesity and 
incident AF. In addition, bioelectrical impedance derived measures of body composition and 
combinations of anthropometric measures of body fat distribution were associated with the 
increased risk of developing AF.24 Also, diabetes at baseline increased proportionally from 
6.9% with a BMI < 25 kg/m2 to 26% in those with a BMI > 30 kg/m2.24 This is probably 
important since a meta-analysis has shown that patients with diabetes had an ~40% greater 
risk of AF compared with those without diabetes.31
The potential implications of these findings are amplified by the fact that obesity has 
reached epidemic proportions worldwide.32 As both AF and obesity are increasing in low-
and middle-income countries, the results should have significant public health implications. 
Importantly, obesity may contribute to the risk of AF-related complications. For example, 
another large cohort study from Denmark has shown that the combination of overweight and 
AF can increase the risk of stroke and death,33 demonstrating that being either overweight or 
obese increases the risk for ischaemic stroke, thromboembolism and death in patients with 
AF, even after adjustment for the CHADS2 and CHA2DS2–VASc risk scores. However, an 
obesity paradox exists. As an example, The Atrial Fibrillation Follow-up Investigation of 
Rhythm Management study, one of the largest multicentre trials of AF including 4060 
patients, found that obese patients with AF appear to have better long-term outcomes than 
non-obese patients.34
A logical consequence of these studies is that overweight/obese patients should be informed 
that there is not only a risk for the commonly known consequences such as diabetes, 
hypertension, coronary artery disease, and heart failure, but also that there is a greater risk of 
developing AF and a subsequent risk of stroke and death.
General dietary considerations
There is currently a paucity of evidence on the effect of unhealthy or extreme weight-loss 
diets on the development of AF (Table 2),35–40 and therefore the association between 
specific dietary factors and AF is tenuous at this time. Only one study falls under this topic, 
by Al Suwaidi et al.42 which enrolled 465 outpatients who were fasting during the month of 
Ramadan. Of the ~5% who had AF at enrolment, only one had to be hospital admitted. 
There were no reports on conversion to or from AF in other patients. All other studies refer 
to specific dietary habits or interventions,41 rather than to extreme diets. Other data are 
limited by virtue of selective reporting, multiple testing, and positive publication bias. Also, 
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many studies are small, some are retrospective, and the effect sizes of dietary exposures are 
modest leading to potential residual confounding, especially since diet is inextricably linked 
with age, race, sex, socioeconomic status, etc.
Blood lipids and fish consumption
Among the modifiable risk factors that can be targeted for AF prevention, caloric intake, and 
physical activity are critical factors that significantly impact weight, blood pressure, risk of 
diabetes mellitus and atherosclerosis, and atrial structure/function.43
What is the impact of blood lipids on risk of AF?
Table 3A summarizes two recent cohort-based studies that evaluated the association of blood 
lipid components with the development of AF during follow-up.44,45 In both, with 
adjustments for age, sex, and race, but no adjustment for BMI, low levels of HDL 
cholesterol, and high levels of plasma triglycerides were associated with increased risk of 
AF. Low-density lipoprotein cholesterol levels (LDL) were not associated with AF risk in 
either study; elevated total cholesterol was associated with risk of AF in one study.44 Both 
studies note the impact of comorbid conditions confounding the association of blood lipid 
levels with AF risk. Thus, evidence for selectively targeting lower plasma LDL or total 
cholesterol as a means of reducing AF risk is weak.
Despite the uncertain association of lipids with incident AF, there is evidence that statins 
protect against AF in patients with chronic stable coronary artery disease, independently of 
reductions in plasma total cholesterol level.50 In experimental studies, statin use protected 
against electrical remodelling associated with atrial tachycardia pacing51 and decreased AF 
inducibility in a canine model of sterile pericarditis.52 Recent meta-analyses suggest that 
statins reduce new onset AF following cardiac surgery, a setting in which inflammatory 
processes are strongly implicated in AF onset.53,54 In contrast to the post-surgical setting, 
large meta-analyses have not demonstrated the efficacy of statins for the primary prevention 
of AF, whilst a heterogeneous benefit is reported for secondary AF prevention.55,56 Statins, 
which impact oxidant and inflammatory mechanisms in addition to lowering plasma LDL 
levels, most likely attenuate AF risk primarily due to effects independent of LDL reduction.
In recognition of this ‘uncoupling’, recent ACC/AHA guidelines for the prevention of 
coronary heart disease have changed from a primary focus on specific LDL target levels to 
one that focuses on the overall risk factor profile of the patient.57 A similar logic may apply 
to AF prevention as well.
Dietary fish consumption vs. studies with fish oil supplements
Older epidemiological studies have suggested that consumption of fatty fish is associated 
with significant health benefits, including reduced risk of AF.58 One recent study in the USA 
(Table 3B) noted a non-significant trend for a lower incidence of AF with higher intake of 
fatty fish (P = 0.09).46 Fish oil is enriched in ω-3 polyunsaturated fatty acids (ω3-PUFA), 
especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and 
docosapentaenoic acid (DPA). The Kuopio study found a trend for the highest vs. lowest 
quartile of plasma EPA + DHA + DPA to be associated with lower risk of AF (P = 0.07). 
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This relationship was modestly significant for DHA (P = 0.02).49 A retrospective analysis of 
a large Danish cohort (n = 55 246), which was a population with high fish consumption, 
suggests that the relationship between fish consumption and AF risk is more complex and U-
shaped, with both low- and high-levels of either fatty fish consumption or consumption of 
the individual ω-3-fatty acids associated with increased risk of AF.47 Also, in the Danish 
population (Table 3B), analysis of adipose DHA and EPA content identified non-significant 
trends for benefit with elevated levels of both DHA and EPA.48 An obvious and important 
confounding factor is the individual burden of adiposity.
While fish oil extracts have demonstrated significant effects on the development of atrial 
fibrosis in the setting of experimental heart failure,59 and on the inducibility of AF after 
experimental cardiac surgery,60 highly purified n3-PUFA supplements, often formulated as 
ethyl esters, have demonstrated either poor or no efficacy in randomized clinical trials for the 
prevention of new onset AF following cardiac surgery,61 or for the prevention of AF 
recurrence.62,63 It remains unclear if the lack of efficacy is related to differences in 
bioavailability,64 to loss of other components in fish that are functionally important, or to 
intrinsic differences between studies in younger experimental animals and those in older 
patients at greatest risk of AF. At present, there is no compelling argument for the use of 
commercially available fish oil supplements for either primary or secondary AF 
prevention.65,66
On the basis of the available epidemiological studies, the current AHA/ACC guidelines for 
individuals with elevated blood LDL levels now recommends consumption of a diet ‘that 
emphasizes intake of vegetables, fruits, and whole grains; includes low-fat dairy products, 
poultry, fish, legumes, non-tropical vegetable oils, and nuts; and limits intake of sweets, 
sugar-sweetened beverages, and red meats’.66
While quite reasonable, this and other similar guidelines do not specifically address diet in 
relation to AF risk. Lacking direct evidence, the above dietary suggestions coupled with an 
emphasis on physical activity and maintenance of a healthy lifestyle and weight seem 
reasonable as interim guidance for AF patients, and for those with significant risk of AF.
Obstructive sleep apnoea
Sleep related breathing disorders are common and ~25% of adults are at risk for sleep 
apnoea of some degree,67 with OSA commonly seen in patients with cardiovascular 
diseases, especially in obese patients and those with Type 2 diabetes mellitus.68 Various 
studies have established that patients with OSA, particularly those with more severe disease, 
are significantly more likely to develop AF, and patients with AF have about twice the risk 
for developing OSA (Table 4).69,70
Patients with AF and those with OSA share several similar characteristics. For example, 
hypertension is common (one-third of OSA) in both conditions, and both occur more 
frequently in men and increase with advancing age.68 Furthermore, increasing BMI plays an 
important role in the development of both OSA and AF.28,71
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The mechanisms for this may be multifactorial, but autonomic dysregulation may connect 
sleep apnoea and AF, independent of other known risk factors. This has been confirmed 
experimentally in dogs72 and clinically.73 In a prospective cohort study,73 a relationship 
among the severity of sleep apnoea syndrome, cardiac arrhythmias, and autonomic 
imbalance was demonstrated.
These observations may have important clinical implications, and large observational studies 
suggest that OSA may be a modifiable risk factor for recurrent AF after cardioversion or 
ablation.74,75 Furthermore, some data support a role for continued positive airway pressure 
(CPAP) therapy in abolishing nocturnal ventricular asystole and improving other 
arrhythmias in patients with OSA.76–79 CPAP therapy was effective in several other 
studies,80–83 but not in heart failure patients.84
Based on the evidence, routine screening for OSA and other sleep-related breathing 
disorders in general practice and in cardiac rehabilitation programmes may be considered if 
clinically indicated. More data are needed to show the benefit of prevention and the 
treatment of OSA and associated improvement of AF incidence, recurrence rate and 
outcomes in patients with new onset or recurrent AF.
Hypertension
Hypertension is a major risk factor for AF (Table 5). In the Framingham Heart Study,85 the 
odds ratios for the development of AF in men and women with hypertension were 1.5 and 
1.4, respectively. Data from the Atherosclerotic Risk in Communities Study18 show that 
approximately one-fifth of the risk of developing AF was attributable to hypertension. The 
optimal systolic blood pressure appears to be 120–130 mmHg with both higher and lower 
blood pressures associated with an increased incidence of AF.25,86,93
Proposed mechanisms include sympathetic activation, activation of the renin-angiotensin-
aldosterone system, atrial dilation, fibrosis, and left ventricular remodelling including 
diastolic dysfunction and left ventricular hypertrophy.43 Hypertension may also lead to 
coronary disease and myocardial infarction, subsequently increasing the risk for AF. Alcohol 
consumption is also a common predisposing factor to both AF and hypertension.
For the primary prevention of AF in a hypertensive population, the optimal on-treatment 
systolic BP goal appears to be <130 mmHg.89 Nevertheless, it remains unclear whether 
different antihypertensive medications affect the development of AF independent of blood 
pressure reduction. In the Losartan Intervention for End Point Reduction in Hypertension 
Study,87 for example, new onset AF occurred less frequently in patients treated with losartan 
compared with patients treated with atenolol, although blood pressure reduction was similar 
in both groups. In another study,88 ACE inhibitors and angiotensin II-receptor blocker 
(ARB) were superior to β-blockers and diuretics for the primary prevention of AF. These 
two studies suggest that the inhibition of the renin-angiotensin system may be associated 
with a decreased risk of new onset AF, incremental to the effect of BP reduction alone.
ARB therapy has also been studied for the secondary prevention of AF. For example, the 
GISSI-AF study90 evaluated the secondary prevention of AF using valsartan, but was not 
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superior to placebo. Follow-up was only for 1 year and it remains possible that the beneficial 
effects of ARBs on atrial remodelling might be seen with a longer study duration.94 In the 
ANTIPAF trial,91 olmesartan did not decrease AF burden compared with placebo in patients 
without structural heart disease.
Additionally, Lip et al.,92 retrospectively analysing data from the SPORTIF III and 
SPORTIF V trials, found that ACEI and ARBs did not result in any difference in stroke or 
systemic embolism in a controlled, anticoagulated AF population. Mortality was lower in the 
AF population over 75 years of age treated with ACEI or ARBs.
The role of aldosterone antagonists in the treatment of AF has been evaluated in the setting 
of heart failure,95 but not in its absence. Given the increasing incidence of AF, additional 
well-conducted studies are needed to clarify the impact of renin–angiotensin–al- dosterone 
system (RAAS) inhibitors on both the primary and secondary prevention of AF.8,96
Diabetes mellitus
Diabetes and elevated blood glucose have been recognized for several years as potential risk 
factors for AF, although there are conflicting results97 (Table 6). Multiple studies31,85,98–104 
report an increased incidence of AF in patients with diabetes. However, there are 
methodological differences that make comparisons among studies difficult. In particular, 
some studies adjusted the results for confounding variables including obesity and 
hypertension, while others did not. When these other risk factors were considered, the risk 
attributable to the development of AF from diabetes was limited. In a meta-analysis of 7 
cohort studies and 4 case-control studies including more than 1 600 000 subjects, Huxley et 
al.31 found that patients with diabetes had a 39% greater risk of developing AF compared 
with individuals without diabetes. In studies that adjusted the risk for confounding variables, 
the relative risk decreased to 1.24 (95% CI 1.06–1.44).
Using a population based, case-control design, Dublin et al. found that patients with longer 
durations of diabetes had a greater risk of AF development. Specifically, the risk of AF was 
3% higher for each year of diabetes treatment, and the risk of AF correlated with worsened 
glycemic control. Hence, better glycemic control (as measured by haemoglobin A1c) was 
associated with a lower risk of AF development. High basal haemoglobin A1c level, 
increased BMI and advanced age were also associated with higher recurrence of AF after 
catheter ablation in patients with diabetes.107
Recently, investigators using the Taiwan National Health Insurance Research Database 
developed a time-dependent Cox proportional hazard model to study the effects of 
metformin on the development of AF.105 The study population included 645 710 patients 
with diabetes taking metformin but not other diabetic medications. Over a 13-year follow-
up, fewer patients taking metformin developed AF, suggesting that metformin had a 
protective effect on the development of AF in diabetic patients.
Additionally, the duration of diabetes appears to be related to a higher risk of 
thromboembolic events in patients with AF. Using data from multiple Danish registries, 
Overvad et al.106 identified 13 722 patients with AF, 12.4% of whom had diabetes. 
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Compared with AF patients without diabetes, thromboembolism was more prevalent and this 
relationship was time-dependent with longer diabetes duration being associated with higher 
rates of thromboembolism and death. A longer diabetes duration was not associated with an 
increased risk of bleeding among AF patients treated with vitamin K antagonists.
In summary, diabetes appears to confer an increased risk for the development of AF, but this 
risk seems less than for other factors including hypertension, obesity, and smoking.18 
Furthermore, a longer diabetes duration and worse glycemic control increases the risk for 
AF and its complications, and in one retrospective study,105 treatment with metformin 
appeared to reduce this risk.
Smoking
Smoking is reported to predict incident AF in individuals of European,98,108–111 
African,108,112 and Japanese113 ancestry (Table 7). Risks of developing incident AF with 
smoking are similar in men and women,98,108–114 and in blacks and whites.108 Multivariable 
risk prediction models for AF indicate that compared with nonsmokers, both current,109,110 
and ever smokers110 have a higher risk of incident AF. Current smoking was responsible for 
~10% of the variability in AF risk.18 Some data also suggest a dose–response relationship, 
with the highest risk of AF observed in individuals with the greatest cigarette-years of 
smoking108 and current smokers with increasing number of cigarettes per day.114 However, 
not all studies have reported an adjusted association between smoking and AF,2,30,115–119 
but the lack of association has been ascribed to several factors including modest numbers of 
cases of AF, combining current, and former smokers,122 adjusting for factors along the 
causal pathway such as myocardial infarction, heart failure, and lung disease114 and 
competing risks of death among smokers.108,122
Whether other forms of tobacco exposure are associated with AF is more equivocal. One 
case report of an elderly woman with several comorbidities suggests a possible temporal 
relation between electronic cigarettes and paroxysms of AF.123 To our knowledge, there is 
no published research linking electronic cigarettes with AF. Similarly, there are no 
prospective data regarding the relation of secondhand smoke to AF. However, one recent 
retrospective study suggested that being exposed to second-hand smoke gestationally or 
living with a smoker during childhood were associated with an increased risk of AF as an 
adult.121 In another study, AF risk was associated with the environmental tobacco use.124 
There have also been case reports of AF associated with chewing nicotine gum.125–127 In 
contrast, a pooled analysis of Swedish studies found current use of snus, a powdered 
smokeless tobacco product, was not significantly associated with incident AF (RR, 1.07; 
0.97–1.19).120 Whether nicotine per se, or other chemicals associated with smoking are 
responsible for the increased risk of AF is uncertain.
Both experimental and human studies support multiple mechanisms linking smoking to AF. 
Nicotine and cigarettes predispose to inflammation,128 atrial electrical alterations,129,130 
atrial fibrosis,131–133 reduced lung function,134,135 myocardial infarction,108 and heart 
failure,108 all of which pre-dispose to AF. Smoking also may be a marker of deprivation and 
unhealthy lifestyle.136,137 An inverse association between socioeconomic status and incident 
AF has been reported, which is partially mediated by other risk factors.138,139
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In individuals with AF, most studies examining the risk of events such as stroke, dementia, 
heart failure, myocardial infarction,5,6 and death have included smoking as a covariate, but 
have not specifically identified risk factors for events.140 Smoking was not a risk factor for 
incident heart failure in individuals with AF.141,142 Neither the CHADS2 nor the CHA2DS2–
VASc scores include smoking as a risk factor for stroke. However, smoking is a risk factor 
for stroke in AF, even accounting for coexisting risk factors,143,144 but this relationship was 
not evident in one study.145 Smoking has also been reported to predict an increased risk for 
intracranial bleeding, mortality,144,146 and the combined outcome of stroke or death145 in 
people with AF.
Although there are no randomized trials proving that smoking cessation reduces the risk of 
AF, the preponderance of evidence supports efforts to encourage individuals to avoid uptake 
or to quit smoking to reduce their risk. Mirroring population trends, smoking rates in 
individuals with AF have declined significantly over time.14 Current smoking was more 
strongly and consistently associated with AF compared with former smoking status in 
most,98,113 but not all114 studies (Table 7). In models excluding individuals with prior 
coronary heart disease and heart failure, former smoking was no longer significantly 
associated with incident AF.98 One biracial observational study noted a nonsignificant trend 
towards reduced rates of AF in individuals who had quit smoking.98
The results of smoking cessation interventions in AF have not been well studied. Despite the 
potential benefits of smoking cessation in AF, individuals with AF were less likely to be 
prescribed smoking cessation aids than those without AF.147 One randomized trial of 
aggressive risk factor reduction, which included smoking cessation in individuals post-AF 
catheter ablation, demonstrated that those randomized to risk factor reduction had lowered 
AF frequency, duration, and symptoms.148
Air pollution
Experimental and epidemiological studies have indicated that air pollution is related to an 
increased prevalence of cardiovascular risk factors, for example diabetes mellitus and 
hypertension, as well as cardiovascular disease.149–154 Fine particular matter (PM2.5) 
produced by burning fossil fuels may contribute to this relationship. The underlying 
pathophysiology has been attributed to an increased inflammatory response to high particle 
exposure, influencing the autonomous nervous system.153
Although fine particle pollution has been linked to stroke in several studies,155–157 it has not 
been found to be associated with the induction of AF. Likewise, epidemiological studies 
have failed to show a relationship between permanently higher fine particle ex-posure and 
AF incidence158,159 (Table 8). Short-term exposure may directly enhance AF susceptibility 
in patients with cardiac disease.160,161
Caffeine
Caffeine is a methylxanthine compound that is chemically similar to theophylline. Caffeine 
is present in tea, coffee, cola, or energy drinks. It has several cardiovascular effects 
increasing neurohormonal and sympathetic nervous system stimulation.162 Therefore, 
caffeine has been addressed as a potential trigger for AF.
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The acute effects of high caffeine loading or even intoxication show minor and overall 
inconsistent evidence for increased susceptibility to supraventricular arrhythmias.163–165 
Habitual caffeine ingestion has been investigated in several prospective cohort studies (Table 
9), but these failed to show any significant relationship to incident AF.168 Also, heavy coffee 
drinking167 failed to demonstrate a significant relationship between caffeine and AF or 
flutter even in very high consumers (10 cups, 1000 mg/day). Overall, caffeine consumption 
on a habitual and regular basis does not seem to increase the incidence of AF.35,166,167 
However, other forms of caffeine ingestion such as energy drinks containing other stimulants 
such as taurine in combination with alcohol, may possibly contribute to an increase of risk, 
at least in case reports.169
Alcohol consumption
Alcohol as a cause of AF has been recognized in the setting of acute consumption, 
commonly described as the ‘holiday heart’.170 Binge drinking (>5 drinks on a single 
occasion) is associated with an increased risk of new onset AF.171
A variety of mechanisms has been proposed for the role of alcohol in contributing to AF as 
triggers or substrate for the arrhythmia including decreased vagal tone, hyper-adrenergic 
state, direct toxic effect on the cardiomyocytes, altered atrial conduction, and shortening of 
refractoriness.172–174
In evaluating the contribution of chronic alcohol consumption to the development of AF, an 
important limitation is that unlike the objective measures available for many of the 
established risk factors for AF, the quantification of alcohol consumption is based on self-
reported levels. Most studies have found an association between heavy alcohol consumption 
and incident AF (Table 10). For example, the Copenhagen City Heart Study observed that 
men consuming >35 drinks/week had a high risk of AF.175 Similarly, the Framingham 
cohort study suggested that heavy alcohol consumption (>36 g/day) significantly increased 
the risk of AF.177 The Women’s Health Study showed that consumption of >2 drinks/day 
was associated with an increased risk of AF.176 A consistent increase in risk of AF with 
chronic, heavy alcohol consumption was confirmed in a meta-analysis, which also 
demonstrated that the association between AF and alcohol consumption was linear.179
Although these large epidemiological datasets have confirmed the association of heavy 
alcohol consumption with AF, recent studies have implicated a contributory role of even 
small quantities of alcohol with an increased risk of AF. Data from 2 large prospective 
Swedish cohorts comprising 79 000 individuals show that, when compared with < 1 drink 
per week, the consumption of 15–21 and >21 drinks per week conferred significant risks of 
developing AF on multivariable analysis.178 This study identified that the risk for AF may 
be most pronounced with liquor; modest for wine and no excess risk was detected with beer. 
In addition, one meta-analysis of seven prospective studies suggested that there was a greater 
risk of AF with even low levels of alcohol consumption.178 In both men and women, each 
drink of alcohol was associated with an 8% increase in relative risk of AF.
The consistent epidemiological relationship between alcohol and AF has led to the 
suggestion that lowering alcohol consumption may be an effective AF preventive strategy.180 
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Recent studies have also highlighted the importance of aggressive risk factor management, 
including reducing alcohol consumption, in maintaining sinus rhythm in patients with 
established AF. In obese and overweight individuals, these studies have established an 
ultimate goal of reducing alcohol consumption to <30 g/week.148 In the context of a directed 
management of risk factors, reducing alcohol consumption has contributed to short-term 
improvements in AF burden26 and AF ablation outcomes,148 as well as long-term 
maintenance of sinus rhythm.28 The above evidence perhaps confirms some atrial toxicity 
related to alcohol consumption. Thus, physicians must not neglect obtaining a detailed 
history on alcohol consumption and providing appropriate counselling to reduce alcohol 
intake, when necessary, in patients with AF.
Recreational drugs
There are numerous reports on the effects on myocardial infarction, ventricular arrhythmias, 
and sudden cardiac death caused by recreational (illicit) drugs such as amphetamine, 
cocaine, and cannabis.181
However, data on these drugs as risk factors for AF per se are sparse. AF has not been 
reported to be associated with amphetamine, heroin, or LSD abuse and there are limited 
reports on the abuse of cannabis, cocaine, ecstasy, and anabolic-androgenic steroids with AF.
Cannabis is the most commonly used recreational drug, which is increasing in Europe. A 
systematic review and a case series with literature review reported that all cases of cannabis-
related AF were among young people without comorbidities.182,183 The underlying 
mechanism is probably adrenergic stimulation and disturbance in microvascular flow 
facilitating AF development by increased pulmonary vein ectopy. Cannabis abuse leading to 
AF is not benign in young and healthy subjects as it may contribute to atrial remodelling 
long-term.182 AF caused by cannabis abuse may be more malignant in older patients having 
other risk factors for thromboembolism. The burden of this problem is probably 
underestimated, given that most illicit cannabis users avoid seeking medical care unless 
serious disease is present.
Physicians should carefully examine for recreational drug abuse in young new onset AF 
patients without known predisposing factors. One case report describes AF in a healthy 
adolescent who had used ecstasy.184 Anabolic–androgenic steroids are often used by young 
athletes to increase their capacity. Thus AF in a young healthy athlete should raise the 
suspicion that illicit drugs may be a possible cause and lead to careful search for drug abuse 
in order to prevent AF and more serious cardiac consequences.185,186
Medications
A number of cardiovascular and non-cardiovascular drugs have been associated with 
increased risk of AF (Table 11). Drug-induced AF has received relatively little attention, and 
the exact incidence is not known.
Many cardiovascular (adenosine, dobutamine, ivabradine) and non-cardiovascular [non-
steroidal anti-inflammatory drugs (NSAIDS), high-dose corticosteroids, and respiratory 
medications as aminophylline] drugs can induce AF.187,189,193 Adenosine is reported to 
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induce AF when used for terminating supraventricular tachycardia with atrioventricular 
nodal involvement. Many patients undergoing cardiac surgery and treated with the inotrope 
dobuta-mine may develop post-operative AF. However, AF is usually transient and of short 
duration. Evidence of chemotherapy-induced AF has been summarized.187,188 
Anthracyclines, melphalan, interleukin-2, and cisplatin appear to be associated with AF, in 
addition to cancer itself that creates an inflammatory arrhythmogenic milieu.194 Several case 
reports of antipsychotic drugs associated with AF have been published,192 include with 
olanzapine (used for the treatment of schizophrenia and bipolar disorder). The antiemetic 
drug ondanse-tron is probably related to AF.187
Whether bisphosphonate drugs against osteoporosis are associated with AF remains 
somewhat controversial. A systematic review and meta-analysis from 2014 concluded that 
AF risk is increased by 40% with intravenous use and 22% by oral use.190 A more recent 
meta-analysis stated that bisphosphonates may modestly increase the risk of AF, but given 
the large reduction in fractures with these drugs, the authors did not recommend changes in 
treatment.191
Drug-induced AF can occur through pharmacological stimulation promoting ectopic 
impulses or by modulating the underlying substrate. Further research is perhaps needed to 
determine the incidence and risk factors of drug-induced AF, and particularly whether 
specific medications increase the risk of thromboembolism or mortality. In patients with a 
new-onset AF, it is reasonable to review the pharmacological history to identify whether any 
of the prescribed drugs may be responsible for the arrhythmia and make a balanced 
judgement on the risks and benefits of the drug use. Drug-induced AF may appear in healthy 
patients, but occurs more frequently in the elderly, after cardiac surgery, and if comorbidities 
and risk factors associated with AF are present. These risk factors include polypharmacy, 
hypertension, major heart disease, chronic obstructive pulmonary disease, and sleep apnoea.
Psychological distress
Psychological distress is prevalent among AFpatients;195–199 ~25–50% have symptoms of 
anxiety and/or depression and fear and worry are common.195–202 There is some evidence 
from ICD patients that acute emotional distress (particularly anger and anxiety)197,203,204 
and depression205 may be antecedents to ventricular arrhythmias but there are no data in 
ICD patients regarding atrial arrhythmias. Only three studies have specifically examined the 
impact of psychological distress on incident AF.206–208
The Framingham Offspring Study examined the association between Type A behaviour, 
anger, and hostility and incident AF. In age-adjusted analyses, anger-out predicted incident 
AF in women, while trait anger, symptoms of anger, and hostility predicted onset of AF in 
men206 (Table 12). On multivariable analyses, symptoms of anger, hostility, and trait-anger 
predicted the 10-year incidence of AF in men but not in women.206 Another analysis of this 
cohort investigated the effect of tension and anxiety on the development of AF.207 In age-
adjusted analyses, tension, and anxiety predicted development of AF in men only. After 
adjustment for confounders, only tension was an independent predictor of incident AF but 
only among men.207
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The absence of an association between psychological distress and the development of AF in 
women was confirmed in the Women’s Health Study.208 In this cohort of 30 746 female 
health professionals aged ≥45 years who were free from cardiovascular disease at baseline, 
771 (2.51%) developed AF over a median 10-year follow-up period. Psychological distress 
was not associated with incident AF in age-adjusted or multivariable analyses.208 These 
findings require replication in other more diverse populations since these cohorts were 
predominantly white, middle-class, and middle-aged204–208 and the effect sizes in the 
Framingham Offspring study were modest.207,208
Psychological distress, particularly depression, is more commonly associated with adverse 
lifestyle choices (smoking, excessive alcohol intake, poor diet, physical inactivity), poorer 
adherence to medication, etc., all of which may increase the likelihood of development of 
other risk factors for AF, and hence predispose people to incident AF. It is also plausible that 
the autonomic nervous system may be the conduit by which AF is linked with psychological 
distress and vice versa. The current evidence is therefore limited and equivocal, and future 
research is needed.
Physical activity and inactivity
Physical activity has profound benefits on lowering cardiovascular morbidity and mortality 
and physical inactivity is a major risk factor for cardiovascular disease. The effects of 
physical activity on the development of AF are less well documented and intervention 
studies on physical activity and the development of AF are lacking (Table 13).
The risk of AF depends on the interaction between individual susceptibility, environment, 
and the degree of physical activity.217 Vigorous exercise may increase risk of sudden cardiac 
death, and even AF in some instances; however, habitual moderate physical activity may 
have several benefits that can reduce the incidence of AF. Lowering heart rate, blood 
pressure, better glucose and lipid control, weight loss, improved endothelial function, and 
lower systemic inflammation are some of the benefits of exercise that may decrease the 
development of AF.97 On the other hand, vigorous activity can cause acute cathecholamine 
fluxes, autonomic tone changes, and atrial stretch, all contributing to AF risk.218–223 
Autonomic influences should also be taken into consideration to decrease aggravation of 
AF218,224
The Euro Heart Survey on AF showed that an autonomic trigger pattern, either adrenergic, 
vagal, or mixed was present in 33% of patients; however, physicians did not choose rhythm 
or rate control medications according to those triggers,224 and inappropriate therapy in vagal 
AF patients enhanced progression of AF.
As stated earlier, obesity begets AF, and increased cardiorespiratory fitness is protective 
against incident AF. Indeed, the CARDIO-FIT study showed that arrhythmia free time was 
greatest in obese patients with high cardiorespiratory fitness. In this study, AF burden and 
symptom severity significantly decreased in the group with cardiorespiratory fitness gain 
over two metabolic equivalent tasks (METs).27
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Different studies have suggested a possible relationship between endurance training and the 
development of AF, although this has not been confirmed in all studies or a Cochrane meta-
analysis.212,214,225–230
Most studies have looked at the effects of endurance training and vigorous exertion in young 
and middle-aged adults. In a study of 44410 men, intense endurance training at age 30 
increased risk of AF later in life whereas moderate intensity decreased AF risk.231 Similar 
findings were reported in older athletes.211 A meta-analysis of several small studies showed 
that risk of AF development in athletes was more than in non-athletes, but referents were not 
age matched and there was variance in the level of endurance across studies.232 Age, years 
of training, and type of sport will all affect the outcome, therefore it is not possible to deduct 
a net conclusion from these studies except that vigorous endurance exercise may have a 
possible and small facilitating effect on AF.
In older adults, prospective epidemiological studies have shown a U-shaped relationship 
between level of physical activity and risk of AF. For example, the Cardiovascular Health 
Study demonstrated that leisure time activity was associated with lower AF incidence in a 
graded manner with lower risk as the intensity increased.211 AF incidence was lower in 
those with moderate exercise compared with no exercise (HR 0.72, 95% CI 0.58–0.89). 
However, high-intensity exercise was not associated with a significantly reduced risk of AF 
(HR 0.87, 95% CI 0.64–1.19). There is also a graded inverse relationship between 
cardiorespiratory fitness and incident AF especially in obese patients.209 In a large 
population-based Swedish cohort, the risk of AF decreased with increased leisure time 
exercise in middle aged and elderly women.210 Inactivity and obesity may lead to diastolic 
dysfunction and left atrial enlargement, and therefore increased AF risk whereas exercise 
training improves diastolic function and reduces left atrial volume.233
Current evidence would suggest that moderate physical activity is associated with better 
cardiovascular health, decreased mortality and decreased risk of AF. The on-going Routine 
vs. Aggressive upstream rhythm Control for prevention of Early atrial fibrillation in 
moderate heart failure (RACE 3) trial is investigating whether the combination of RAAS 
modulators, statins, and cardiac rehabilitation interventions to promote a better lifestyle 
including physical activity, weight reduction, and a healthy diet, may reduce progression of 
AF.234
Genetic predisposition and risk of AF
About 5% of patients with AF and 15% with lone AF referred for the evaluation of 
arrhythmias have family history of arrhythmias.235 Population-based studies demonstrated 
association between family history and risk of AF development236–241 (Table 14), which 
become stronger with increased numbers of affected first degree relatives and younger age. 
Several genes and loci linked to AF and its substrate were identified in families, individuals, 
and different populations,242–244 still there are genes in development state with unknown 
effects and risk associated with AF.245,246 AF with genetic predisposition is defined as 
monogenic when related to inherited cardiomyopathies and as polygenic in the presence of 
common gene variants associated with early AF onset in population.247,248
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The evidence of genetic predisposition to AF is evolving, and more studies are needed to 
clarify the role of various genes in AF development and as the genetic predisposition is a 
non-modifiable risk factor more studies are needed to establish whether intervention on 
modifiable risk factors can decrease risk of AF in populations with genetic predisposition.
Hyperthyroidism and other endocrine disorders
Among endocrine disorders, hyperthyroidism and diabetes mellitus (see above) are 
commonly associated with risk of developing AF,31,103,249,250 while hypothyroidism poses 
no or reduces risk for arrhythmia.249,251,252
Observational cohort and registry studies (Table 15) reported AF incidence rates of 4.6–
13.8% in overt hyperthyroidism, 8.512.7% in subclinical hyperthyroidism, and 7.3% in high-
normal euthyroidism [based on thyroid stimulating hormone (TSH) level].249–251,253–257
The risk of new-onset AF in hyperthyroidism depends on the level of thyroid dysfunction. 
AF is increased by 42% in overt hyperthyroidism, by 31% in subclinical hyperthyroidism, 
and by 12% in high-normal euthyroidism.249 Patients with subclinical forms are 1.68-fold 
more likely to develop AF during long-term follow-up, and those with suppressed TSH 
values have been shown to possess 2.54-fold higher risk of incident AF compared with 
euthyroid populations.249,251,253,255,256 Though the evidence on risk of AF in individuals 
with high-normal euthyroidism is limited, the Rotterdam study demonstrated an increased 
risk of AF in individuals with high-normal thyroid function (based on TSH level)257 and in 
subjects <65 years old with higher free thyroxine levels within normal range.258 Nonetheless 
the evidence on demographic and cardiovascular disease risk factors associated with AF in 
thyroid dysfunction is scarce. In overt hyperthyroidism, age > 65 years, male sex, 
comorbidities like coronary artery disease, chronic heart failure, and valvular heart disease 
were reported as predictors of arrhythmia.259 In the subclinical form, age and sex were 
shown to affect the incident risk of AF, being significant in all age categories in women, and 
young male individuals, except in the older (>65 years) male population.249 In a recent 
meta-analysis,256 the risk of AF in subclinical hyperthyroidism was associated with male 
sex, but was not altered by the presence of cardiovascular disease or its risk factors. In 
another study, subclinical hyperthyroidism was shown to be a predictor of AF in elderly 
individuals, along with advanced age category (>75 years), male sex, diabetes mellitus, 
hypertension, and heart failure.257
AF risk diminishes during antithyroid treatment,249 with spontaneous restoration of sinus 
rhythm in ~76% of patients260 and reduction of arrhythmia on long-term monitoring.259 
Sinus rhythm restoration rates are also higher in elderly patients with overt and subclinical 
hyperthyroidism without cardiovascular disease and its risk factors, when compared with 
those with comorbidities.253 After restoration of an euthyroid state and electrical 
cardioversion or catheter ablation for persistent AF, long-term sinus rhythm maintenance 
rates have been shown to be either higher in patients with hyperthyroidism261 or did not 
differ from those without history of thyroid dysfunction.262,263
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Hyperthyroidism had been long considered to be associated with higher thromboembolic 
risk,65 but recent studies demonstrated that thyroid disease is not an independent predictor of 
AF-related complications such as thromboembolism and stroke.264–266
Thus, prevention of AF in overt and subclinical hyperthyroidism should include measures, 
such as controlling thyroid function, treatment of associated cardiovascular diseases, and 
modification of risk factors. More research is needed regarding risk factors and prevention of 
AF in populations with high-normal euthyroidism based on TSH level and normal thyroid 
function with higher free thyroxine levels within normal range.
Electrophysiological considerations
Atrial premature beats triggering AF—Atrial fibrillation can be maintained by rapid 
focal firing or by reentrant activity. The actual mechanism by which triggers (ectopic beats) 
initiate AF is unclear, but an important topic of research. Prior reports have mapped 
spontaneous ectopic triggers for AF and demonstrated their spatial diversity in both atria and 
prematurity in rate.267 Several mechanisms produce abnormal impulse formation that can 
cause focal ectopic activity: abnormal automaticity and triggered activity. Abnormal 
automaticity relies on an increased Phase 4 depolarization in cells that normally have a flat 
Phase 4. The (upre-gulation of the) pacemaker current/f (funny current) may play an 
important role in this mechanism.
Triggered activity consists of depolarizations occurring after the action potential: delayed 
after depolarizations (DADs) or within the action potential: late Phase 3 early after 
depolarizations. These triggers often originate from predilected sites in the atria, such as the 
ostia of the pulmonary vein sleeves.267 DADs are thought the most common cause of focal 
atrial ectopic firing and are caused by diastolic Ca++ leak from the sarcoplasmic reticulum 
via SR Ca++-release channels (RyR2) and the Na+/Ca++ exchange (NCX)268
To maintain AF, these ectopic beats must be sustained to produce rapid driver activity or 
form the trigger to initiate reentry in a vulnerable substrate. AF remodels the atrial electrical 
properties to promote both initiation and propagation. It is well known that electrical 
remodelling consists of shortening of the duration of the action potential and depressed 
intracellular Ca++ transients. Besides the involvement of the regular ion channels, also the/Na 
late current plays a possible role.
Structural remodelling plays another important role in the initiation and maintenance of 
AF.269 Various pathways play a role including the RAAS, inflammation, and fat deposition 
leading to enlarged atria, hypertrophy, fibrosis, and myolysis.270–276 Indeed, the first 
manifestation of AF usually occurs after years of atrial remodelling.273 Once AF develops, it 
causes marked changes in atrial electrophysiology (electrical remodelling) in addition to 
further deterioration of the structural remodelling processes, constituting a vicious cycle in 
which ‘AF begets AF’,271 making it challenging to restore and maintain sinus rhythm.273,274
Molecular mechanisms: Abnormal cellular Ca++ handling is typically seen in AF patients. 
Defective Ca++ handling promotes spontaneous ryanodine receptor (RyR2)-mediated Ca++ 
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release in atrial cells of patients with AF. Phosphorylation ofRyR2 and CAMKII is increased 
in AF. Increases in NCX expression/activity are also common noted in AF.
Supraventricular tachyarrhythmias causing AF—Supraventricular tachyarrhythmias 
(SVT) and pre-excitation may associate with AF.275–278 In 169 paroxysmal SVT out-
patients, AF incidence was 19% over 2.5 years, assessed by remote monitoring (Figure 
1).277 Atrial flutter and AF coexist even more often, one arrhythmia potentially reinforcing 
the other.279 Finally, flutter is frequently accompanied by atrioventricular nodal re-entry 
tachycardia (AVNRT)280
Causal mechanisms include tachycardia-related atrial ischaemia or dispersion of conduction 
and refractoriness, which can be facilitated by background atrial remodelling. Enhanced 
vagal tone is another mechanism.281 Digitalis may cause shortening of atrial 
refractoriness282 and also associate SVT or atrial flutter with AF. The same may hold for 
adenosine, which may elicit AF when given for the termination of SVT, and potentially 
cause haemodynamic deterioration.283 Due to conduction slowing, flutter may emerge under 
drug treatment for AF through activation of a sleeping circuit, seen especially with 
flecainide or propafenone (class-lc flutter).284 Late onset AVNRT may occur upon 
cardiovascular ageing, in turn producing triggers and substrate for both AVNRT, as well as 
AF and flutter.285 Similarly, atrial remodelling (e.g. in the setting of hypertension) may 
connect atrial tachycardia and atrial flutter to AF. Last, but not least, AF and SVT may also 
simply associate due to the presence of both arrhythmia mechanisms including frequent 
pulmonary vein ectopy, as part of paroxysmal AF, but triggering the SVT substrate 
meanwhile.
In pre-excitation syndrome, the very presence of the accessory atrioventricular pathway (i.e. 
in the absence of atrial remodelling like in ‘classic’ AF) has been associated with local atrial 
arrhythmo-genesis and hence AF. Conduction dispersion emerges during retrograde pathway 
conduction after ventricular premature beats or during orthodromic tachycardia. 
Asymptomatic pre-excitation usually is not associated with AF, although younger patients as 
well as those with inducible SVT or AF and those with a short anterograde refractory period 
may be at risk.286 AF and pre-excitation, together with premature conduction disease, may 
occur in a rare genetic form of hypertrophic cardiomyopathy due to AMP kinase gene 
mutation deregulating cellular energy homoeostasis.287
When PAF and SVT associate, medical (including upstream antiremodelling) therapy may 
apply for both although ablation of both mechanisms seems most appropriate. Ablation of 
SVT or flutter may abolish AF or make it better amenable to rhythm control, although 
frequently electrophysiologists will perform pulmonary vein isolation at the same time. 
Ablation of the accessory pathway, in patients with overt pre-excitation suffering from AF, 
may prevent further AF attacks288 and is the preferred treatment also to prevent rare sudden 
death due to ventricular fibrillation. If these patients refuse ablation or complications are 
expected (e.g. atriovenricular block), then medical therapy may be indicated.236,289 Usually 
flecai- nide or propafenone are prescribed and amiodarone may be needed in the presence of 
concurrent cardiac disease. After ablation of class Ic flutter it is advocated to continue drug 
treatment for suppression of the initial AF although after isthmus ablation AF attacks may 
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subside spontaneously. To avoid repeat procedures, SVT mechanisms should be checked 
electrophysiologically during any AF ablation, especially in the younger non-remodelled AF 
patients (Figure 2).
Post-operative atrial fibrillation
AF after cardiac surgery occurs in 30% of patients,290 and is also frequent after thoracic 
surgery. This arrhythmia is associated with higher occurrence of heart failure and stroke, 
both resulting in increased hospitalization and healthcarecosts291 and also correlating with a 
higher rate of other serious complications [increased risk of in-hospital morbidity and 
mortality, and increased long-term risk of stroke]292 Post-operative AF usually is developed 
between Days 1 and 4 after surgical intervention. The mechanisms underlying the 
development of AF after cardiac surgery are not completely understood, but are thought to 
be multifactorial.291 Numerous predisposing factors such as advanced age, hypertension, 
diabetes, left atrial enlargement, left ventricular hypertrophy, type of intervention, and the 
presence of cardiac valvular disease, intraoperative and post-operative factors such as atrial 
injury or ischaemia, can favour the development of post-operative AF.293
Different drugs have been investigated to prevent post-operative AF. Centrally acting β-
adrenergic receptor-blocking agents tend to reduce sympathetic efferent activity and promote 
cardiac vagal outflow.294 Current guidelines strongly recommend using b-blockers to reduce 
post-operative AF incidence65 and for that reason, preoperative b-blocker administration is 
standard in all patients without contraindications. Indeed, the European guidelines 
recommend that treatment should be started at least 1 week before surgery with a b1-blocker 
without intrinsic sympathomimetic activity.65 A large meta-analysis of 27 randomized 
controlled trials with 3 840 patients, reported that the incidence of post-operative AF in 
control patients was 33% compared with 19% in those taking b-blockers, although an 
inexplicable and marked heterogeneity was found between trials.295 The importance of b-
blockers is also affirmed by the two- to five-fold increase in AF after cardiac surgery, when 
b-blockers are discontinued post-operatively.296
The effectiveness of sotalol vs. placebo and sotalol vs. conventional β-blockers in preventing 
AF after surgery has been analysed in several clinical trials. A recent meta-analysis297 
analysed 8 trials (1294 patients in total) evaluating the effect of sotalol to reduce post-
operative AF, and demonstrated a reduction in AF incidence (37% in placebo group vs. 17% 
in sotalol group) with no significant heterogeneity between trials. Sotalol and other β-
blockers were compared directly in 4 trials including 900 patients.295 Once again, sotalol 
reduced the incidence of post-operative AF from 22% in the other b-blocker group to 12% in 
the sotalol group with no significant heterogeneity. However, the use of sotalol places 
patients at risk of bradycardia and torsade de pointes, especially in those with electrolyte 
disturbances, reason why its use in post-operative AF is limited.65
Several studies have analysed the impact of amiodarone on postoperative AF, with more than 
10 randomized placebo-controlled trials. In a recent meta-analysis,297 prophylactic 
amiodarone decreased the incidence of post-operative AF (OR 0.43; 95% CI 0.34–0.54) and 
significantly shortened the duration of hospital stay, reduced the incidence of stroke and of 
post-operative ventricular tachyarrhythmia, but not post-operative mortality.298 European 
et al. Page 19
Eur J Prev Cardiol. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
guidelines recommend considering preoperative amiodarone for patients at high risk for 
post-operative AF.65
It is recognized that the use of statins is associated with a 22–34% lower risk of post-
operative AF.65 The largest and most robust trial of atorvastatin carried out to date, the 
Atorvastatin for Reduction of Myocardial Dysrhythmia After cardiac surgery study 
(ARMYDA-3),299 demonstrated that atorvastatin treatment conferred a 61% reduction in 
risk of post-operative AF in multivariable analyses. A recent large randomized trial did not 
show beneficial effects of rosuvastatin on incidence of complications or AF after cardiac 
surgery.300
Other drugs have been studied,297,301 but most show conflicting results. For example, no 
significant effect of RAAS-related medications on the occurrence of AF following cardiac 
surgery291 and safety concerns about the potential risk of associated renal dysfunction. A 
meta-analysis demonstrated a significant reduction in postoperative AF using 
corticosteroids,302 but we should take into account the potential adverse effects on glucose 
metabolism, wound healing, and infection. Other drugs explored included magnesium 
supplements, colchicine, non-steroidal anti-inflammatory drugs, and antioxidant agents (i.e. 
polyunsaturated fatty acids or N-acetylcysteine).301
Current European guidelines recommend b-blockers and amio-darone as prophylactic 
therapies for post-operative AF. However, new pharmacological agents, with anti-
inflammatory, and remodelling properties could take a place in the prevention of 
postoperative AF. Further research in this field is needed.
Upstream therapies to prevent AF
Upstream therapy refers to the use of non-ion-channel anti-arrhyth-mic drugs that modify 
the atrial substrate upstream of AF to prevent new-onset AF (i.e. primary prevention) or 
recurrent AF (i.e. secondary prevention). It includes treatment with RAAS blockers [ACEIs, 
ARBs, and mineralocorticoid receptor antagonists (MRAs)], statins, and possibly n3-
PUFAs.303,304 RAAS blockers may prevent or reduce atrial structural remodelling by 
decreasing fibrosis and improving haemodynamics. Interestingly, recent data support the 
favourable effects of physical activity, i.e. moderate exercise on AF burden.211
Upstream therapy has been encouraging in animal experiments, hypothesis-generating small 
clinical studies, and primary prevention studies.303,304 However, only few data support its 
beneficial effect for secondary prevention of AF. ACEIs and ARBs seem valuable, especially 
when added to amiodarone.274,305 Mineralocorticoid receptor antagonists may be even more 
effective in preventing AF recurrences but few data are available.306,307
Statins, known for their lipid-lowering capacities, have pleiotropic properties such as 
reduction of inflammation and oxidative stress. Through these properties, statins may play a 
protective role against AF development. However, results regarding effectiveness of statins 
have been inconclusive.304
The effects of PUFAs have been well demonstrated in animal model, but limited evidence in 
secondary prevention of AF is available.303,304
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Favourable effects of lifestyle changes, including moderate exercise, have been 
demonstrated in selected patients.26,27,148,201 In a recent randomized trial, in obese AF 
patients, weight management, including physical activity and counselling, was compared 
with general lifestyle advice.26 In addition to a significant reduction of BMI, AF symptoms 
and burden were significantly reduced in the aggressive weight management group. This 
finding was confirmed in the Longterm Effect of Goal directed weight management on AF 
Cohort: a 5 Year follow-up (LEGACY) trial, again in obese AF patients.28 Progressive 
weight loss was associated with a reduced AF burden and symptoms and, interestingly, left 
atrial volume.
Overall, upstream therapy may be effective in primary prevention. The disappointing results 
regarding secondary prevention of AF may have been caused by inclusion of patients in 
whom the extent of remodelling was too severe and irreversible due to a long history of AF 
and underlying diseases.273,274 Inclusion of patients, in whom remodelling processes are 
less advanced, may improve outcome, in addition to tailoring certain upstream therapies to 
distinct patient groups (e.g. lifestyle changes in obese inactive patients).
Risk factors leading to AF development as risk factors for thromboembolic complications
Stroke prevention is central to the management of AF,308 and many of the risk factors 
leading to AF development are also risk factors for its thromboembolic complications. 
Whilst AF increases the risk of stroke five-fold, this risk is not homogeneous and depends 
on the presence of various stroke risk factors.309 Some risk factors are independent 
predictors of stroke risk, and have been used to formulate various stroke risk stratification 
schemes, such as the CHA2DS2-VASc score, which is now recommended in guidelines.310 
There are also various stroke risk modifiers, such as OSA311 and renal impairment,312 that 
have been associated with an increased stroke risk per se, although their additive predictive 
(and practical) value over and above validated stroke risk scores is less certain. Whether 
treatment of sleep apnoea with continuous positive airway pressure reduces stroke risk is 
unproved.311
Some risk factors within the CHA2DS2-VASc score, such as age, prior stroke, or 
thromboembolism, vascular disease, and female sex, are non-modifiable. Also, prior heart 
failure especially if associated with a hospital admission with decompensation, confers an 
excess of stroke risk.313 Hence, efforts to minimize hospitalizations and decompensation of 
heart failure may help. Diabetes mellitus is less modifiable, but the duration of diabetes may 
predispose to an even higher risk of stroke and thromboembolism 107).
In a systematic review of stroke risk factors, a history of hypertension or uncontrolled 
hypertension conferred an increase in stroke risk,309 but clearly, well-controlled 
hypertension has a lower risk of stroke compared with uncontrolled hypertension.314 
Hypertension is also the commonest comorbidity associated with AF. Thus, patients with AF 
should have blood pressures ~130/80 mmHg, reflecting the fact that AF could be considered 
a manifestation of hypertensive target organ damage, and given that stroke risk starts to rise 
beyond SBPs of 130 mmHg.314
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Other potentially modifiable risk factors such as obesity, smoking, and alcohol excess have 
been related to an increased risk of stroke and mortality,33,315,316 although intervention 
studies to show how these would successfully decrease the risk of stroke in AF are lacking. 
Data from cohort studies very recently indicated that weight reduction and improvement in 
physical fitness may reduce the recurrence of AF.27 Also, rhythm control measures, such as 
cardioversion and ablation, may help in symptom management, and improve functional 
status, but randomized trials, clearly showing that such interventions reduce stroke in a 
broad range of unselected AF cohorts are lacking.317 Observational data, in selected cohorts, 
suggest that successful catheter ablation may be associated with a lowered stroke risk318 but, 
given that asymptomatic recurrences and late recurrence are recognized phenomena, 
guidelines recommend continuation of oral anticoagulation (OAC), in patients with a 
CHA2DS2-VASc score of ≥2, irrespective of apparent success of rhythm control.317
Modifiable factors to reduce the risk of stroke can include attention to quality of 
anticoagulation control for a patient taking a VKA (e.g. warfarin). The quality of 
anticoagulation control is usually quantified by the average time in therapeutic range (TTR) 
and a TTR of >70% is recommended.319 However, TTR can be influenced by various 
clinical risk factors, especially in inception cohorts where warfarin is introduced.320 Thus, in 
newly diagnosed and previously anticoagulated naive AF patients, a ‘trial of warfarin’ prior 
to considering a non-VKA oral anticoagulant (NOAC) is not recommended given that TTR 
is likely to be subtherapeutic in the early phase of warfarin initiation, leading to an increased 
risk of stroke.321 The SAMe–TT2R2 score322 has been proposed to help decision-making 
between patients who are likely to do well on a VKA with high TTR (i.e. SAMe-TT2R2 
score 0–2) and those unlikely to do well on a VKA with poor TTR (SAMe-TT2R2 score >2), 
where a NOAC would be a better first option.323,324 Thus, simple clinical decisionmaking, 
based on clinical risk factors that influence poor TTR as a stroke risk factor (within the 
SAMe– TT2R2 score), can help inform treatment decisions that would reduce the likelihood 
of labile INRs, and its adverse consequences such as stroke, bleeding, and death.325
Patient values/preferences
Many of the risk factors for the development of AF are to a certain extent preventable and/or 
modifiable via lifestyle choices such as diet, smoking, alcohol, recreational drug use, 
physical activity, maintenance of a healthy weight, and adherence to medication to control 
concomitant conditions (hypertension, diabetes, hyperthyroidism, etc.) and therefore 
potentially under individuals’ conscious control.326 In addition, risk factors are likely to be 
cumulative in increasing risk of incident AF.98,111,115 However, an individual’s ability to 
‘control’ these factors may be limited by socioeconomic circumstances, access to healthcare 
and medications, health literacy, etc. Therefore, primary prevention of disease requires 
greater public awareness of the causes and consequences of the disease and how a person 
can modify his/her own risk of developing it. Thus, improving the general populations’ 
understanding and perception of AF (what it is, how it develops, associated stroke risk), of 
how their lifestyle impacts their risk of developing AF, and identifying strategies to change 
their health beliefs and health behaviours to reduce their risk of progressing to AF, requires 
both an individual approach plus global public health campaigns. Since lifestyle choices 
have significant impacts on all diseases, healthcare professionals should utilize contacts with 
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patients to discuss diet, smoking, alcohol/drug use, and exercise, offer appropriate education, 
advice, and intervention(s), and support people to adopt and maintain health-promoting 
behaviours to help reduce their risk of developing AF (and other diseases) Tables 16 and 17.
Conclusions
In the present document, the determinants and triggers of atrial fibrillation (AF) are 
extensively discussed and it appears clear that prevention of this disorder requires a tailored 
approach to the individual patient. Moreover, certain modifiable risk factors, such smoking, 
alcohol abuse, and lack of physical activity, are deemed important components of a 
preventive strategy.33,315,316
In order to reduce the risk of AF, both an individual approach and global public health 
campaigns are required.
Many of the risk factors for AF are preventable and/or modifiable via lifestyle choices. As 
explained, modifying an inappropriate diet, quitting smoking, abstaining from alcohol and 
recreational drugs, and participating in regular physical activity programmes are efficient 
strategies under the patient’s control.
A lifetime approach to cardiovascular risk modification is required (Figure 3). General 
physicians have a relevant role in this strategy, by monitoring their patients closely and 
adopting a lower threshold for educational intervention. A particular relevance to the scope 
is assigned to the implementation of nutritional interventions and to promote regular 
exercise programmes and sport participation. However, the greatest effort should be paid by 
policy makers in order to improve the population’s capability to achieve and maintain a 
healthy cardiovascular lifestyle. The most adverse risk profile is actually prevalent among 
individuals with low-socioeconomic status, poorer educational attainment, and limited 
access to healthcare.
The prevention of AF, more than other cardiovascular disorders, requires an approach that 
targets the global population, and a new political vision in the management of the healthcare 
system. In a society with available limited financial resources, it appears wise to modify the 
risk factors and quality of life of the largest majority of general population, more than 
developing sophisticated devices to shortly prolong the life of a few terminal patients.
Finally, special attention should be paid to the adolescent and young generations, who 
paradoxically are not at low cardiac risk, because of the epidemic incidence of obesity, 
inappropriate nutritional behaviour, smoking and alcohol abuse, and a widespread sedentary 
lifestyle.
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Abbreviations and acronyms
ACEI angiotensin converting enzyme inhibitors
AF atrial fibrillation
ARB angiotensin receptor blockers
AVNRT atrioventricular nodal re-entry tachycardia
BMI body mass index
CHADS2 cardiac failure, hypertension, age, diabetes, stroke 
(doubled)
CHA2DS2-VASc congestive heart failure or left ventricular dysfunction, 
hypertension, age ≥75 (doubled), diabetes, stroke/transient 
ischaemic attack (doubled)-vascular disease, age 65–74, 
sex category (female)
CI confidence interval
FU follow-up
HR hazard ratio
HDL high-density lipoprotein cholesterol
ICD implantable cardioverter defibrillators
LA left atrium
LDL low-density lipoprotein cholesterol
LV left ventricle
NOAC non-VKA oral anticoagulant
OAC oral anticoagulation
OR odds ratio
OSA obstructive sleep apnoea
n3-PUFA v-3 polyunsaturated fatty acids
RAAS renin–angiotensin–aldosterone system
RR relative risk
SBP systolic blood pressure
SAMe-TT2R2 sex (female), age (<60 years), medical history, treatment 
(interacting drugs, e.g. amiodarone for rhythm control), 
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tobacco use (within 2 years) (doubled), Race (non-
Caucasian) (doubled)
SVT supraventricular tachyarrhythmia
VKA vitamin K antagonist
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Figure 1. 
Graph showing time to occurrence of symptomatic atrial fibrillation in all 169 patients with 
paroxysmal supraventricular tachycardia. Y-Axis reflects the percentage of patients free 
from atrial fibrillation. (Reprinted from reference 277: J Am Coll Cardiol Vol.25, Hamer 
ME, Wilkinson WE, Clair WK, Page RL, McCarthy EA, Pritchett EL. Incidence of 
symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia. 
number, p. 984–8, Copyright 1995, with permission from Elsevier.)
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Figure 2. 
Management of supraventricular tachycardias causing AF. AF, atrial fibrillation; AAD, 
antiarrhythmic drug; PAF, paroxysmal AF; SVT, supraventricular tachycardia.
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Figure 3. 
Lifetime approach to primary prevention of AF. AF, atrial fibrillation.
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Table 11
Medications associated with risk of incident AF
Medications
Common (>20%) Dobutamine,187 Cisplatin187,188
Infrequent (5–20%) Anthracyclines,187,188 Melphalan,187,188 Interleukin-2,187,188 NSAIDS,189 Bisphosphonates190,191
Rare (<5%) Adenosine,187 Corticosteroids,187 Aminophylline,187 Antipsychotics,192 Ivabradine193 Ondansetron187
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Table 16
Consensus statements on AF prevention I: risk factors and lifestyle modification
Risk factor/trigger Recommendations for clinical practice Recommendations for research
Obesity Inform overweight and obese patients of greater 
risk of developing AF and a subsequent risk of 
stroke and death.
Assess BMI and start lifestyle programmes if 
BMI is overweight or obese
More studies are needed on how to effectively prevent 
weight gain and promote weight loss in individuals who 
are overweight or obese
More randomized controlled studies with long-term 
follow-up (>5 years) are needed to clarify the obesity 
paradox
General dietary considerations Recommend healthy nutrition and lifestyle to 
reduce risk of AF
Mediterranean diet enriched with olive oil may 
reduce risk of AF and its complications
More studies are needed on: the effect of unhealthy 
nutrition on risk of AF Whether modification of diet 
reduces risk of arrhythmia
Blood lipids, fish consumption Inform patients with low HDL (<40 mg/dL) and 
high triglyceride (TGs >200 mg/dL) levels of risk 
of AF and its complications
Recommend to patients with abnormal blood 
lipids to consume of a diet ‘that emphasizes 
intake of vegetables, fruits, and whole grains; 
includes low-fat dairy products, poultry, fish, 
legumes, non-tropical vegetable oils, and nuts; 
and limits intake of sweets, sugar-sweetened 
beverages, and red meats’66
Recommend combination of diet with moderate 
physical activity and maintenance of a healthy 
lifestyle and weight
Lacking direct evidence, more studies are needed to 
define whether modification of blood lipids reduces the 
risk of AF.
Obstructive sleep apnoea Inform patients with obstructive sleep apnoea that 
there is a greater risk of developing AF and their 
subsequent risk of stroke and death.
Assess by anamnesis (snoring, daytime fatigue) 
the possibility of OSA Refer to specialised clinic, 
as needed.
More studies are needed:
To investigate how comorbidity in patients with 
obstructive sleep apnoea affects the risk of AF
To show the benefit of diagnostic efforts and the effect of 
treatment with CPAP.
On adequate assessment of presence of OSA in AF 
population.
To show reduced risk of AF in well powered RCTs using 
systematic therapeutic approach together with other 
lifestyle changes
Hypertension Uncontrolled blood pressure is associated with 
AF risk
Adequately assess patients at risk
Control BP to reduce AF risk
Additional well-conducted secondary AF prevention 
trials will be important to define target SBP optimal to 
prevent AF
Implement in RCTs together with other lifestyle 
management
Diabetes mellitus Longer duration of diabetes and worse glycemic 
control are associated with increased AF risk
Control diabetes to reduce AF risk
More research is needed on the effect of glycemic 
control on AF risk in patients with diabetes
Tobacco smoking Intensively encourage children, young and older 
adults not to begin smoking. In individuals who 
smoke support smoking cessation to prevent AF 
incidence, recurrence, symptoms, and 
complications.
Primordial prevention. Support efforts to prevent 
the uptake of tobacco smoking.
Primary prevention. Encourage individuals to 
quit smoking.
Secondary prevention. In individuals with AF 
promote efforts to quit smoking to improve AF 
frequency, duration, and symptoms
Investigate whether electronic cigarettes and second 
hand smoke are associated with an increased risk of 
new-onset AF, and in individuals with prevalent AF, 
whether electronic cigarettes and second hand smoke are 
associated with AF recurrence and AF symptoms.
In individuals with AF, examine the efficacy and 
effectiveness of smoking cessation interventions to 
decrease the risk of stroke, myocardial infarction, 
chronic kidney disease, dementia, and all-cause 
mortality.
Air pollution No association with chronic exposure; patients 
prone to AF should refrain from severe pollution 
exposure.
Overall data are scarce and should be increased 
specifically aimed at incidence of AF in patients with 
known cardiac disease.
Caffeine No increase in risk, rather a reduced association, 
even for heavy consumption.
Data should be extended to randomized intervention 
studies addressing caffeine consumption in patients with 
paroxysmal AF
Alcohol Moderate-heavy and binge drinking increases AF 
risk
To reduce AF risk:
More intervention studies are needed on the effect of 
alcohol consumption reduction on AF risk
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Risk factor/trigger Recommendations for clinical practice Recommendations for research
Recommend to avoid binge drinking (>4 drinks 
in women and >5 drinks in men on a single 
occasion)
Recommend to refrain consumption to no more 
than 2 drinks per day for men and 1 drink per day 
for women
Obtain a detailed history on alcohol consumption
Provide appropriate counselling to reduce alcohol 
consumption in patients with AF
Medications Many drugs increase AF risk; common (>20%) - 
dobutamine, cisplatin; infrequent (5–20 %) - 
anthracyclines, melphalan, interleukin, NSAIDS, 
bisphosphonates; rare (<5 %) - adenosine, 
corticosteroids, aminophylline, antipsychotics, 
ivabradin, ondansetron.
In patients with new-onset AF, review the 
pharmacological history to identify whether any 
of the prescribed drugs may cause the 
arrhythmia.
More research on the effects on AF incidence for drug 
induced new-onset AF is needed, as many studies show 
conflicting results.
Also more research is needed on which medications 
cause increased risk of AF.
Recreational drugs Recreational drugs (cannabis, ecstasy and 
anabolic-androgenic steroids) may increase risk 
of AF.
Examine for recreational drug abuse in new-onset 
AF
Encourage avoidance of recreational drugs.
More research is needed on the effect of illicit drugs, 
particularly cannabis, on new-onset AF, as most of the 
evidence is from case reports
Psychological distress Identify significant psychological distress, 
particularly depression and anxiety, and treat 
appropriately to reduce the likelihood of adverse 
lifestyle choices (smoking, excessive alcohol 
intake, poor diet, physical inactivity) and poorer 
adherence to medication and lifestyle 
modification, all of which may increase the 
likelihood of development of other risk factors 
for AF, and hence predispose people to incident 
AF and other chronic diseases.
Further investigation of the impact of psychological 
distress on the development of AF in more diverse 
populations is warranted since the current limited 
evidence is based predominantly on white, middle-class, 
and middle-aged cohorts, and is only evident in men.
Physical activity Recommend daily moderate exercise to reduce 
risk of AF
Role of physical activity clearly warrants further 
research, plus genetics involved in AF in excessive 
sports
AF, atrial fibrillation; BMI, body mass index; BP, blood pressure; CPAP, continuous positive airway pressure; HDL, high-densiy lipoprotein 
cholesterol; OSA, obstructive sleep apnoea; RCT, randomised controlled trial; SBP, systolic blood pressure.
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Table 17
Consensus statements on AF prevention II: management of associated conditions
Risk factor/trigger Recommendations for clinical practice Recommendations for research
Hyperthyroidism Overt and subclinical hyperthyroidism 
increase AF risk
Control thyroid function in patients at risk of 
AF
Treat associated cardiovascular diseases and 
consider modification of risk factors
More research is needed regarding risk factors and prevention of AF 
in populations with high-normal thyroid function (based on TSH 
level) and individuals with higher level of free thyroxin within 
normal range.
Supraventricular 
tachyarrhythmias and 
paroxysmal AF
In patients with SVT and paroxysmal AF: 
Ablate SVT, continue antiarrhythmic drugs or 
ablate AF as needed.
Checking for potential SVT substrate should 
be considered in patients with isolated PAF 
referred for ablation
Additional studies on prevention of AF in patients with SVT are 
needed
Post-operative AF β-Blockers and amiodarone are indicated for 
prophylaxis of post-operative AF
More research is needed on use of pharmacological agents with 
anti-inflammatory and anti-remodelling properties, statins and other 
possible drugs for prevention of post-operative AF
Upstream therapies – Investigation of the long term effects of sustained secondary 
prevention with upstream therapies starting before AF in people at 
risk and early after AF diagnosis are required
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; SVT, supraventricular tachycardia; TSH, thyroid stimulating hormone.
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